Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

Performance

52-Week Range 11.8% below 52-week high

346.21

160.1152W Low 392.7052W High

1 Week 1.5% below 1-week high

260.771W Low 351.641W High

Praxis Precision Medicines, Inc. - Common Stock (PRAX) traded between $160.11 and $392.70 over the past 52 weeks and last traded at $346.21, 11.8% below its 52-week high. Over the past week it ranged between $260.77 and $351.64.

Past 12 Months

+31.8%

+37.7%

-10.4%

-0.2%

+20.9%

+88.6%

1W +$83.62

1M +$94.83

3M -$40.12

6M -$0.63

YTD +$59.81

1Y +$162.65

PRAX was +88.6% over the past year, -0.2% over six months, +20.9% year to date, +31.8% in the last week.

12 Months vs Market

PRAX

+88.6%

DIA

+9.4%

SPY

+11.2%

QQQ

+11.1%

IWM

+15.9%

Over the past 12 months PRAX returned +88.6% versus DIA (Dow) +9.4%, SPY (S&P 500) +11.2%, QQQ (Nasdaq 100) +11.1% and IWM (Russell 2000) +15.9%.

Volume & Liquidity 0.00× 3-mo avg

Today 5 3-mo avg 455.8K

612.8K

518.5K

455.8K

475.2K

YTD

470.2K

529.8K

PRAX most recently traded 5 shares against a 3-month average daily volume of 455.8K.

More News

October 27, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2026

Praxis (PRAX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Praxis Precision Medicines Q2 Earnings Call Highlights ↗

August 07, 2026

Via MarketBeat

August 06, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 04, 2026

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

July 30, 2026

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

July 07, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 02, 2026

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

June 29, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

June 22, 2026

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

June 04, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2026

Praxis Precision Medicines Provides Vormatrigine Program Update

June 01, 2026

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗

May 31, 2026

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗

May 26, 2026

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗

May 21, 2026

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026